



26 February 2026

ASX RELEASE

The Calmer Co. Secures \$2m per Annum Minimum Revenue via Strategic CO₂ Kava Supply Agreement

Brisbane, Australia – The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation, sleep support, and healthier alternatives to alcohol, is pleased to announce that it has entered into a material Master Supply Agreement with a leading U.S.-based kava functional beverage company, covering the supply of premium CO₂-extracted kava ingredients.

The agreement is expected to deliver approximately \$2 million in revenue per annum, subject to a minimum commitment of AU\$1,581,884 over 24 months, production scheduling, delivery timing and foreign exchange movements.

Commercial Highlights

- Material 24-month supply agreement for high-specification CO₂ kava extract
- Minimum contracted revenue of approximately of AU\$1,581,884 over the 24 months (**Commitment**), but it is anticipated, based on the quarterly product inventory requested by the customer, that demand will likely equate to revenue of approximately \$2 million per annum during the term
- Quarterly supply framework aligned to customer production planning
- USD-denominated pricing with defined review mechanisms linked to raw material movements
- Non-exclusive arrangement, preserving the Company's ability to supply other global customers
- Engage directly with us on Investor Hub via this [link](#).



Founder and CEO, Zane Yoshida, commented:

"This agreement represents a significant milestone in the execution of our B2B ingredients strategy. Securing minimum contracted revenue provides strong revenue visibility and validates our investment in vertically integrated sourcing and advanced CO₂ extraction capability.

The structure of the agreement allows both parties to scale volumes over time as demand for kava-based functional beverages continues to expand in the U.S. market."

Details of Agreement

The term of the agreement is 24 months.

While the contract does not require that the customer purchase a minimum quantity of products quarterly, the Company has agreed to maintain a minimum stipulated quarterly inventory of the products at the request of the customer.

The Customer must purchase any shortfall in the Commitment by the end of the 24 month term, if not already purchased.

The contract other contains typical commercial supply terms, including mutual warranties, insurance requirements, deposits on placement of orders, payment terms and sale price adjustment based on the purity of kavalactone delivered by the Company, and may be terminated on 30 days' notice for an unremedied breach.

Strategic Rationale

The agreement further positions The Calmer Co. as a preferred supplier of premium kava ingredients to international beverage and wellness brands, supporting the Company's strategy to expand higher-margin B2B revenues and diversify beyond consumer packaged goods.

Outlook

The Company expects the agreement to contribute materially to B2B revenue growth. Revenue recognition will depend on purchase order timing, production schedules and delivery under the agreement.

ASX Compliance Disclosure

Pursuant to ASX Compliance Update 02/25:



- it does not consider the identity of the counterparty to the agreement to be information that a reasonable person would expect to have a material effect on the price or value of the Company's securities;
- confirms that this announcement contains all material information relevant to assessing the impact of the contract on the price or value of the Company's securities, and is not misleading by omission; and
- includes a description of the counterparty that is sufficient to describe any market sensitive information about the counterparty, including its standing and creditworthiness.

This announcement has been approved by the Board of Directors.

ends

For further information

Investor & Media Relations

Zane Yoshida

investors@thecalmerco.com

About The Calmer Co.

The Calmer Co. International Limited (ASX:CCO) is a fast growing beverage business leveraging a global opportunity in kava and other natural products that replace alcohol and support relaxation and sleep.

Our products are delivered to consumers globally through e-commerce channels and blue-chip retail distribution partners, supported by a reliable farm to shelf supply chain.

The product range includes drinking powders, natural and flavoured kava shots, concentrates and capsules, sold under the brands Fiji Kava®, Taki Mai® and Danodan Hempworks in markets including USA, Australia, New Zealand, China and the Pacific Islands.

Forward looking statements

This ASX release includes certain forward-looking statements that are based on information and assumptions known to date and are subject to various risks and

For personal use only



uncertainties. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. These factors may cause actual results to differ materially from those expressed in the statements contained in this announcement.

For personal use only

